Dual-Targeted Therapies Plus Chemo Improve Objective Response Rate in BRAF V600E Metastatic CRC
By Elana Gotkine HealthDay Reporter
TUESDAY, Feb. 4, 2025 -- For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard chemotherapy (modified folinic acid [or levofolinate], fluorouracil, and oxaliplatin regimen [mFOLFOX6]) is associated with an improved objective response rate compared with standard of care (SOC), according to a study published online Jan. 25 in Nature Medicine. The research was published to coincide with the American Society of Clinical Oncology annual Gastrointestinal Cancers Symposium, held from Jan. 23 to 25 in San Francisco.
Scott Kopetz, M.D., Ph.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues examined EC+mFOLFOX6 versus SOC in patients with previously untreated BRAF V600E mCRC in the phase 3 BREAKWATER study.
At data cutoff, data were not mature for the dual primary end point of progression-free survival. However, the researchers found that BREAKWATER met the other dual primary end point of objective response rate, demonstrating a significant and clinically relevant improvement (60.9 versus 40.0 percent for EC+mFOLFOX6 versus SOC; odds ratio, 2.443). The median duration of response was 13.9 and 11.1 months, respectively. The hazard ratio was 0.47 at this first interim analysis of overall survival. The safety profiles were consistent with those known for each agent; serious adverse event rates were 37.7 and 34.6 percent in the EC+mFOLFOX6 and SOC groups, respectively.
"These encouraging data support this regimen to potentially become the new SOC in BRAF V600E-mutant mCRC; prespecified analyses of mature progression-free survival and overall survival data are planned," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Pfizer, which sponsored BREAKWATER; support was also received from other pharmaceutical companies.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Providing Personalized Risk Messages Has No Overall Effect on CRC Screening Uptake or Test Completion
WEDNESDAY, Sept. 3, 2025 -- Including personalized risk for advanced colorectal neoplasia (ACN) in a decision aid or provider notification has no overall effect in terms of...
Medical Debt in Collections Persists After Cancer Diagnosis
TUESDAY, Sept. 2, 2025 -- Modest amounts of medical debt in collections persist for years after cancer diagnosis, according to a study published online Aug. 28 in JAMA...
Autoimmune Diseases Linked to Digestive System Cancers
FRIDAY, Aug. 15, 2025 -- Autoimmune diseases are associated with certain digestive system cancers, according to a review published in the September issue of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.